Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (OST) in Australia is low despite methadone being a significant contributor to opioid overdose deaths. Our aim was to explore barriers and facilitators for OST patients to engage in THN. We used a descriptive qualitative design with thematic analysis to gain insight into naloxone uptake by people engaged in an OST program in regional Australia. Eleven participants were interviewed; eight had previously engaged with THN. Barriers to THN included limited knowledge and understanding, lack of information, and not personally experiencing an overdose. Facilitators included having a traumatic experience of overdose, knowledge and understanding of THN ...
INTRODUCTION AND AIMS: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Austr...
ABSTRACT Naloxone, an injectable opiate antagonist, can immediately reverse an opi-ate overdose and ...
There have been increases in prescriptions of high strength opioids for chronic non-cancer pain (CNC...
Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (O...
Abstract: Introduction and Aims: Opioid overdose prevention programs providing take-home naloxone ha...
Aims. Before proceeding with the introduction of an overdose fatality prevention programme including...
Aims: To investigate the perspectives and experiences of service providers regarding provision of ta...
Abstract Background Drug-induced and drug-related deaths have been increasing for the past decade th...
Abstract Background Naloxone has been evidenced widely as a means of reducing mortality resulting fr...
Objective: Take-home naloxone (THN) is recommended in response to pharmaceutical opioid-related mort...
“Once I’d done it once it was like writing your name”: Lived experience of take-home naloxone admini...
BackgroundFatal opioid overdose is a pressing public health concern in the United States. Addressing...
Abstract Background Naloxone is a safe and effective medication to help reverse opioid overdose. Pr...
Introduction and Aims: Take-home naloxone (THN) programs have been operating in Australia since 2012...
There have been increases in the prescribing of high strength opioids for chronic non-cancer pain (C...
INTRODUCTION AND AIMS: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Austr...
ABSTRACT Naloxone, an injectable opiate antagonist, can immediately reverse an opi-ate overdose and ...
There have been increases in prescriptions of high strength opioids for chronic non-cancer pain (CNC...
Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (O...
Abstract: Introduction and Aims: Opioid overdose prevention programs providing take-home naloxone ha...
Aims. Before proceeding with the introduction of an overdose fatality prevention programme including...
Aims: To investigate the perspectives and experiences of service providers regarding provision of ta...
Abstract Background Drug-induced and drug-related deaths have been increasing for the past decade th...
Abstract Background Naloxone has been evidenced widely as a means of reducing mortality resulting fr...
Objective: Take-home naloxone (THN) is recommended in response to pharmaceutical opioid-related mort...
“Once I’d done it once it was like writing your name”: Lived experience of take-home naloxone admini...
BackgroundFatal opioid overdose is a pressing public health concern in the United States. Addressing...
Abstract Background Naloxone is a safe and effective medication to help reverse opioid overdose. Pr...
Introduction and Aims: Take-home naloxone (THN) programs have been operating in Australia since 2012...
There have been increases in the prescribing of high strength opioids for chronic non-cancer pain (C...
INTRODUCTION AND AIMS: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Austr...
ABSTRACT Naloxone, an injectable opiate antagonist, can immediately reverse an opi-ate overdose and ...
There have been increases in prescriptions of high strength opioids for chronic non-cancer pain (CNC...